Renal Cell Carcinoma News
New study finds a prevalence of benign pathologic findings after PN of 30.9%.
Researchers theorize that KPNA2 expression could be used in the future to stratify risk groups among patients with renal cell carcinoma (RCC).
A review article examines the challenges in pathologic staging and grade reporting for patients with renal cell carcinoma.
Insights into controversial results of trials evaluating adjuvant vascular endothelial growth factor tyrosine kinase inhibitors in high-risk renal cell carcinoma.
PD-L1 tumor expression was found not to be a predictive biomarker for cabozantinib efficacy in mRCC.
A flat-dosing schedule of nivolumab (480 mg every 4 weeks) showed pharmacologic activity and safety similar to other schedules.
Long-term oncologic outcomes of patients with sporadic RCC who underwent robotic tumor enucleation suggest the procedure is safe.
An antibody-drug conjugate targeting ectonucleotide pyrophosphatase/phosphodiesterase 3 conjugated to monomethyl auristatin F had some antitumor activity in patients with advanced, metastatic renal cell carcinoma.
When sunitinib was given as an adjuvant therapy in renal cell carcinoma, patients reported worse symptoms and lower health-related quality of life scores.
Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.
The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.
Biomarkers May Predict Patient Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma
Circulating blood biomarkers related to angiogenesis may help clinicians predict who will have a robust response to sunitinib.
Research focused on renal cell carcinoma appears to confirm the potential etiologic role of vitamin D binding protein in cancer.
Obesity is associated with an increased likelihood of clear cell and possibly chromophobe renal cell carcinoma.
The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.
Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.
The incorporation and efficacy of targeted therapies to management has called into question the conventional standard of using cytoreductive nephrectomy prior to sunitinib.
Researchers assigned 38 patients with metastatic renal cell carcinoma to receive pegilodecakin plus nivolumab or pembrolizumab.
Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.
The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Fermented Dairy and Cancer
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Could Cytostatic Drugs Unleash Antitumor Immunity in Lung Cancer?
- Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
- Fermented Dairy and Cancer
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC